Achieve Life Sciences Inc Market Cap ($639.57 Million)
Market Cap & Net Worth: Achieve Life Sciences Inc (ACHV)
Achieve Life Sciences Inc market cap. Achieve Life Sciences Inc (NASDAQ:ACHV) has a market capitalization of $639.57 Million ($639.57 Million) as of November 9, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10686 globally and #2836 in its home market, demonstrating a -6.54% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Achieve Life Sciences Inc's stock price $6.72 by its total outstanding shares 102659057 (102.66 Million). Also see Achieve Life Sciences Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Achieve Life Sciences Inc Market Cap History (2015–2026)
Achieve Life Sciences Inc market cap history from 2015 to 2026. Data shows change from $273.28 Billion to $689.87 Million (-45.05% CAGR). Check Achieve Life Sciences Inc share price for real-time trading data and today's change.
Index Memberships
Achieve Life Sciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.59 Trillion | 0.02% | #300 of 976 |
|
NASDAQ Composite
IXIC
|
$39.00 Trillion | 0.00% | #1103 of 3165 |
Weight: Achieve Life Sciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Achieve Life Sciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Achieve Life Sciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ACHV shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
22303.91x
Achieve Life Sciences Inc's market cap is 22303.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $112.90 Billion | $5.06 Million | -$20.13 Million | 22303.91x | N/A |
Competitor Companies of ACHV by Market Capitalization
Companies near Achieve Life Sciences Inc in the global market cap rankings as of November 9, 2026. Also see ACHV asset base for a full breakdown of the balance sheet.
Key companies related to Achieve Life Sciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Achieve Life Sciences Inc (2015–2026)
Market capitalization of Achieve Life Sciences Inc from 2015 to today. Between 2015 and today, Achieve Life Sciences Inc's market cap moved from $273.28 Billion to $ 689.87 Million, with a yearly change of -45.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $689.87 Million | +35.21% |
| 2025 | $510.22 Million | +41.19% |
| 2024 | $361.36 Million | -14.56% |
| 2023 | $422.96 Million | +68.16% |
| 2022 | $251.51 Million | -68.51% |
| 2021 | $798.69 Million | -3.95% |
| 2020 | $831.54 Million | -23.57% |
| 2019 | $1.09 Billion | -56.21% |
| 2018 | $2.48 Billion | -90.99% |
| 2017 | $27.58 Billion | -75.57% |
| 2016 | $112.90 Billion | -58.69% |
| 2015 | $273.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Achieve Life Sciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $639.57 Million USD |
| MoneyControl | $639.57 Million USD |
| MarketWatch | $639.57 Million USD |
| marketcap.company | $639.57 Million USD |
| Reuters | $639.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreement… Read more